Shire/Noven Methypatch For ADHD To Be Reviewed By Psychopharm Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Companies seek indication for once-daily methylphenidate patch for the treatment of attention deficit/hyperactivity disorder in children ages six to 12 years.
You may also be interested in...
Shire/Noven's Daytrana Receives FDA Wake-up Call: Side Effects Greater Than Concerta, Agency Says
FDA will ask FDA's Psychopharmacologic Drugs Advisory Committee whether the methylphenidate patch is "acceptably safe" for approval at Dec. 2 meeting.
Shire/Noven's Daytrana Receives FDA Wake-up Call: Side Effects Greater Than Concerta, Agency Says
FDA will ask FDA's Psychopharmacologic Drugs Advisory Committee whether the methylphenidate patch is "acceptably safe" for approval at Dec. 2 meeting.
Tamiflu, Vioxx Pediatric Adverse Event Reports To Be Presented At Committee Meeting
FDA’s Pediatric Advisory Committee will also hear pediatric adverse event reports on Agrylin, Paraplatin, Diflucan, Camptosar, Ferrlecit and Imitrex at Nov. 18 meeting.